Responsiveness and minimal important difference (MID) estimates for SF-36 and patient-reported outcomes.
| MID Improvement, (n = 17) | MID Deterioration, (n = 21) | Correlation with Anchor | Effect Size | SRM | |
|---|---|---|---|---|---|
| Pain | −14.71 (31.25) | −0.95 (18.82)** | 0.30* | −0.55 | −0.49 |
| PGA | −11.76 (25.06) | −2.86 (18.88)* | 0.31** | −0.50 | −0.55 |
| HAQ | −0.27 (0.42) | 0.095 (0.18)** | 0.30** | −0.22 | −0.22 |
| SF-36 scales | |||||
| PF | 4.41 (14.99) | −6.25 (18.77)** | −0.34** | 0.35 | 0.37 |
| RP | 11.76 (44.30) | −11.25 (36.70)* | −0.29* | 0.41 | 0.39 |
| BP | 12.35 (19.83) | −5.45 (15.63)** | −0.41** | 0.53 | 0.59 |
| GH | −2.94 (12.34) | −3.75 (15.02)* | −0.30** | 0.25 | 0.24 |
| VT | 7.94 (11.46) | −5.25 (15.68)** | −0.28** | 0.28 | 0.35 |
| SF | 5.06 (22.50) | −2.78 (17.45)* | −0.27* | 0.26 | 0.31 |
| RE | 3.96 (52.60) | −10.0 (37.62)* | −0.23* | 0.27 | 0.26 |
| MH | 1.41 (8.36) | 0.00 (14.85)* | −0.28* | 0.19 | 0.31 |
| PCS | 3.74 (8.51) | −3.97 (10.46)** | −0.43** | 0.49 | 0.55 |
| MCS | 1.77 (8.60) | −0.70 (8.37)* | −0.24* | 0.19 | 0.28 |